DBV Technologies S.A.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| DBVT | ATTO | ACRS | ABCL | QTTB | LKFT | |
|---|---|---|---|---|---|---|
| Market cap | 624.64M | 712.16M | 570.34M | 3.98B | 267.03M | 2.25B |
| P/E (TTM) | — | — | — | — | 2.5 | 3.2 |
| Forward P/E | -25.6 | -6.6 | -5.1 | -16.1 | -8.8 | -28.6 |
| Price/book | 4.2 | -0.5 | 4.1 | 4.2 | 2.0 | 12.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −28.30% | −30.27% | +65.49% | +159.70% | +266.53% | +7.56% |
| Today | −1.68% | +2.16% | −1.60% | +0.82% | +2.40% | +6.03% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All DBVT news ›DBV Technologies to Participate in Upcoming November Investor Conferences
Châtillon, France, November 2, 2026 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced the company will participate at the following…
DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years
Châtillon, France, September 29, 2026 DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq…
DBV Technologies Surges Ahead in Q3 2026: Regulatory Milestones and Quality Assurance in Focus
DBV Technologies, a pioneering biotech company specializing in allergy treatments, has made significant strides in its third quarter of 2026, as revealed during the company's recent conference call. The key highlight of this period was the…
DBV Technologies GAAP EPS of -$0.14 beats by $0.07
DBV Technologies press release (DBVT): Q3 GAAP EPS of -$0.14 beats by $0.07. Operating income of $1.6M Reported cash and cash equivalents of $165.7 million as o - DBV Technologies press release (DBVT): Q3 GAAP EPS of -$0.14 beats by $0.07.…
DBV Technologies S.A. (DBVT) Q3 2026 Earnings Call Transcript
DBV Technologies S.A. (DBVT) Q3 2026 Earnings Call October 28, 2026 5:00 PM EDT Daniel Tassé - CEO & DirectorKevin Malobisky - Chief Operations OfficerVirginie Simone Jeanine Boucinha - Chief Financial OfficerPharis Mohideen - Chief…
DBV expects cash runway into Q3 2027 as it advances sequential FDA reviews for VIASKIN Peanut BLAs
DBV Technologies Q3 2026 earnings: BLA filing progress, FDA inspection readiness, manufacturing risks, and cash runway into 2027. Earnings Call Insights: DBV Technologies (DBVT) Q3 2026 - "The highlight of the quarter was the filing of our…
Reviewing DBV Technologies (NASDAQ:DBVT) and Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Posted by Defense World Staff on Oct 17th, 2026 DBV Technologies (NASDAQ:DBVT – Get Free Report) and Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast…
DBV Technologies S.A. (NASDAQ:DBVT) Stock Has Consensus Target Price of $48.50 According to Analysts
Posted by Danessa Lincoln on Oct 15th, 2026 Read Our Latest Report on DBVT DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The…
DBV Technologies (NASDAQ:DBVT) Sets New 52-Week Low – What’s Next?
Posted by Danessa Lincoln on Oct 14th, 2026 DBV Technologies S.A. (NASDAQ:DBVT – Get Free Report)’s share price hit a new 52-week low during mid-day trading on Wednesday. The company traded as low as $8.90 and last traded at $9.03, with a…
More from 1 other outlet
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com3
- seekingalpha.com3
- defenseworld.net2
- themarketsdaily.com2
- markets.financialcontent.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 12 articles, not a forecast.